Biogen, Sangamo Ink Neuro Deal for New “Gene Regulation” Therapies

Posted by |2020-03-02T02:30:08-08:00February 28th, 2020|

Biogen is opening up its checkbook again to get its hands on innovative approaches to some brain disorders that have proven especially recalcitrant to new types of treatment. The Cambridge, MA-based neuroscience drug developer is paying gene editing company Sangamo Therapeutics (NASDAQ: SGMO) $350 million up front in a collaboration on potential one-time treatments for […]

Biohaven’s Migraine Pill Is the Latest CGRP Drug to Win the FDA’s OK

Posted by |2020-02-27T15:22:58-08:00February 27th, 2020|

A Biohaven Pharmaceutical migraine drug has won FDA approval, clearing the way to the market for a new treatment option for the millions of people who suffer from the debilitating condition. The Biohaven (NYSE: BHVN) drug rimegepant (Nurtec) was developed for acute migraine in adults, treating a migraine attack as it occurs. The drug, a […]

Esperion’s Combo Pill for Lowering Cholesterol Levels Wins FDA Nod

Posted by |2020-02-26T15:47:19-08:00February 26th, 2020|

An Esperion Therapeutics drug that pairs two cholesterol-lowering medicines in a single pill has been approved by the FDA, the second regulatory nod for the company in less than a week. The reglator’s decision covers the combination of Esperion’s bempedoic acid (Nexletol) and ezetimibe, an older generic drug for reducing levels of the “bad” form […]

Skyhawk’s Terry Connolly Takes On New Role as Chief Operating Officer

Posted by |2020-02-25T11:04:46-08:00February 25th, 2020|

Skyhawk Therapeutics has appointed Terry Connolly to serve as its chief operating officer. He had spent the past year as the Waltham, MA, company’s chief business officer. Before joining Skyhawk, Connolly held multiple roles at Celgene. Skyhawk is developing small molecule drugs that correct errors in RNA splicing. The company’s preclinical pipeline includes one program […]

UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System

Posted by |2020-02-24T21:35:23-08:00February 24th, 2020|

At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced […]

Invetx Fetches $15M to Develop Biologic Drugs for Man’s Best Friend

Posted by |2020-02-23T21:01:20-08:00February 23rd, 2020|

Veterinarians have a saying that a cat is not a small dog, says Invetx CEO Juergen Horn. Obviously, a dog of any size isn’t the same as a human. But Horn, a veterinarian, says there are enough similarities between the species to take the science behind biological drugs for people and apply it to animals. […]

Bio Roundup: Agile Approval, Coronavirus Collabs, Spruce’s $88M & More

Posted by |2020-02-23T02:30:08-08:00February 21st, 2020|

The price of insulin, a life-saving treatment discovered a century ago, has been a flashpoint amid the broader drug pricing debate. The FDA is trying to tame high insulin prices by encouraging price competition. The FDA has historically regarded insulin as a drug. But insulin isn’t a chemical drug, it’s made from biological material. Under […]

SeaGen Adds Five Prime Therapeutics Antibodies in Licensing Deal

Posted by |2020-02-20T14:36:01-08:00February 20th, 2020|

Since a major restructuring at Five Prime Therapeutics in October that kicked off a wind-down of most of its research and preclinical efforts, the company has been looking to add to its partnerships portfolio. On Wednesday, South San Francisco-based Five Prime (NASDAQ: FPRX) said it inked one such new deal. The agreement, a license deal […]

EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device

Posted by |2020-02-19T15:30:12-08:00February 19th, 2020|

Many companies are working to develop new drugs that target harmful proteins associated with neurodegenerative diseases. EnClear Therapies has raised a $10 million Series A round of financing from a syndicate of investors to advance a device that it says could help treat neurodegenerative diseases by filtering out such proteins from cerebral spinal fluid (CSF), […]

Five Prime, Bristol Pancreatic Cancer Drug Combo Fails Phase 2 Test

Posted by |2020-02-18T18:32:26-08:00February 18th, 2020|

A year ago Five Prime Therapeutics cut a fifth of its workforce to save money as its worked to advance its clinical-stage drugs for solid tumor cancers. On Tuesday the company said one of those drugs, cabiralizumab, a Five Prime antibody that Bristol-Myers Squibb (NYSE: BMY) was testing in combination with its cancer immunotherapy nivolumab […]

Agile Therapeutics Wins FDA Nod for Twirla Contraceptive Patch

Posted by |2020-02-18T02:30:07-08:00February 14th, 2020|

A contraceptive patch developed by Agile Therapeutics was awarded FDA approval late Friday, clearing the way for a new birth control option to reach the market. The Agile (NASDAQ: AGRX) product, called Twirla, deliver delivers a combination of hormones via a proprietary skin patch applied once a week. It’s the first FDA approved product for the […]

Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks

Posted by |2020-02-13T16:21:20-08:00February 13th, 2020|

Eisai is withdrawing weight-loss drug lorcaserin after a post-marketing study found a higher incidence of cancer in patients who took the medicine. The FDA said Thursday that its request for removal of the product from the market is voluntary, but Eisai has already started the process for doing so. The withdrawal follows an FDA alert […]
Go to Top